2016年12月25日星期日

Statins Impair Immune System Function

The statin drug Zocor (simvastatin) has been shown to directly compromise the immune response1 to an opportunistic infection.  This is not good news for any person taking any statin, as the type of impairment involved seriously compromises basic immune system function.
The production of cholesterol is much like an automobile assembly line, except with multiple branches that build other things at the same time (a novel system of efficiency).  The various molecules produced are vital to your survival.  Indeed, cholesterol synthesis is the backbone of survival.  The primary cholesterol production line is called the HMG-CoA reductase pathway.  Important branches include the production of selenoproteins that run your antioxidants and thyroid, as well as the production of coenzyme Q10 and vitamin D.  One of these branches involves the production of novel compounds called isoprenoids (geranylgeranyl pyrophosphate and farnesyl pyrophosphate).  Isoprenoids also occur in nature in fat-soluble nutrients like carotenes.  In fact, the power of tocotrienol vitamin E compared to regular vitamin E is due primarily to the fact that tocotrienols have a side chain molecule that is an isoprenoid.  These isoprenoids play a vital role in attaching fatty substances to proteins, a process called protein prenylation.  Proper protein prenylation is required for the healthy function of many cells in your body, including the prevention of cancer.  Taking any statin reduces the protein prenylation activities in your body via suppressing the production of the isporenoids needed to carry out this activity.  This is a highly undesirable side effect of statins.
The new research looked into the function of macrophages, important members of your front line immune troops.  Some macrophages were treated with Zocor at a relevant physiologic dose and others were not.  They were then exposed to a common bacterial infection.  The Zocor-treated macrophages experienced a double-negative whammy.  Their ability to engulf the bacteria was crippled.  Next, the macrophages generated excessive inappropriate inflammatory signals.  The researchers traced the molecular malfunction to the fact that the statin blocked proper protein prenylation within the macrophage, crippling its function.
While I have tried to make this rather complex issue as simple as possible to understand, the bottom line is that this is a highly adverse effect on human immunity that will cause more severe infections in humans or allow low-grade infections to gain a hold within the human body and wreak havoc to health.  In turn, these infections will increase the overall inflammatory burden that is now known to be a primary contributing factor to poor health and all “diseases of aging.”  On this point alone the use of statins should be banned for 95% of the people currently taking them as there is no way the benefits could possibly outweigh the risks.  The medical profession prescribing these drugs invariably ignores or doesn’t understand this type of study and hopes the general public doesn’t understand health well enough to be concerned.

The Statin Scam Marches On

Considering that tens of millions of Americans now take statins to lower cholesterol, the following headline was conspicuously absent from the major media this month:  “Statins Found to Turn On Gene that Causes Muscle Damage.”  It’s now a fact of science; a new study shows that taking statins destroys your muscle to a greater or lesser degree.  And let’s not forget that the heart is a muscle. 
Place this study juxtaposed to another rather interesting recent finding:  the more fit you are the longer you will live – and the two just don’t add up.  How can you destroy muscle and be more fit?  You can’t.  Sure you can drug your cholesterol number lower, but will you be healthier, fit, and live longer?
In the new study researchers found that statins activate a gene signal in muscles called atrogen-1.  When this gene activates it targets key muscle proteins for destruction.  The activation of this gene drives the process of muscle atrophy and muscle wasting.  It is induced in cardiac muscle in failing hearts.  Why on earth would any person want this gene activated by a drug? 
The researchers tested statin-taking humans who were complaining of severe muscle pain.  Muscle biopsy found that the atrogen-1 gene was activated, compared to people with severe muscle pain not on statins and controls.  They went on to show through various experiments that statins activate the gene.  This is extremely bad news for any person taking a statin.
Right now doctors ignore the majority of muscle aches and pains caused by statins, and in their mind only consider the problem serious when it is debilitating (rhabdomyolysis), which apparently happens less than 1% of the time.  However, at least 5% - 7% of statin users experience significant muscle problems.  The number is greater than 10% if a person is taking the now commonly prescribed higher doses.  And if a person is trying to be fit and exercise the number jumps to 25%.  These numbers are clearly on the low end as it has now been shown that doctors are ignoring their patients, not reporting the side effects of statins to the FDA, and telling them the side effects they are experiencing are not from the drug! 
This new science shows that as soon as the atrogen-1 gene is activated by statins it starts destroying muscle.  This means that even mild aches or pains while taking a statin is a sign that muscle is being destroyed, an entirely new and sobering perspective on the side effects of statins.  Statins directly work against being physically fit, as is evidenced by the difficulty statin users have exercising without troubling symptoms.
Cardiomyopathy (serious weakening of the heart muscle) is a known adverse and often not reported side effect of statin therapy, previously thought to be the result of a statin-induced coenzyme Q10 deficiency.  It is likely that the combination of Q10 deficiency with atrogen-1 activation is behind this problem.

Statins – Perversion of Science for Profit

The statin industry is a 20-billion-a-year propaganda machine, producing more yearly revenues from one class of drug than all professional U.S. sports combined.  Just like any hot-selling drug on the market, negative studies are discouraged to say the least.  They are either thrown in the trash can when they don’t work out or critical researchers are often blackmailed, meaning if they publish something negative they will never again get research money from the industry.  These well known tactics discourage basic research on drug-related toxicity problems.
When statistics are honestly looked at in the case of using statins for many years to prevent a first heart attack, for every life that is saved (1% over 10 years use) statins cause an equal number of adverse deaths due to accidents, infection, suicide, and cancer (1% over 10 years use).  This means that as a general public health measure, which is now the lion’s share of current statin use, they are an ineffectual waste of money.  It has now been proven that middle-age men would be better off taking an aspirin a day for a tiny fraction of the cost (of course there are many supplement options).  Statin-taking for a number of years does not reduce mortality rate.  None of these facts faze the statin industry, which keeps churning out positive spin and moving right along regardless of the damage being doing and the money wasted.
The fraud of statins inside one’s body centers on the regulation of an enzyme known as HMG CoA reductase.  Statins work by reducing the function of this enzyme, the higher the dose the more the enzyme is reduced, and the less cholesterol is made.  It is well known that individuals with naturally lower cholesterol (LDL at 130, total less than 200) in their 40s and 50s have fewer cardiovascular problems as they grow older.  However, taking a statin to reduce cholesterol to these levels or even lower is not the same thing as natural healthy function. 
In healthy individuals with lower cholesterol the HMG CoA reductase enzyme is active at a high level as part of health.  It is part of a complex communication system within the body that regulates energy, immunity, fat metabolism, leptin, cellular thyroid hormone activity, liver-related synthesis, stress tolerance, adrenal function, sex hormone synthesis, and brain function.  This system is core to survival!  The high activity of this enzyme is a type of metabolic fitness, similar to the idea of muscle fitness.  The enzyme is very active in a healthy state for a variety of important and vital needs.
Drugging this enzyme is similar to making a person get around in a wheelchair, whether they need one or not.  If you put a person’s metabolism in a statin-induced straightjacket, then maybe Humpty Dumpty won’t fall off the wall so easily.  That may be a useful concept for someone in brittle cardiovascular health, but it has little to do with the average person concerned about general cardiovascular well being and maintaining a healthy level of fitness and vitality. 
Doctors don’t use statins to try and reduce HMG CoA activity a little bit, with the idea of approximating some type of healthy function of the enzyme (the lowest and least toxic dose possible to provide improvement).  Doctors actually could care less what healthy function of the enzyme actually is.  Rather, the new “gold standard of medical care” is to batter the enzyme into a state of submission so that cholesterol levels are abnormally low.  Any apparent benefits of a statin, many of which are falsely touted, is accomplished by poisoning some aspect of health.  How long can such a charade be allowed to continue on millions of unsuspecting Americans?  Why won’t the FDA demand drug companies include a correct risk profile as part of the labeling?  As normal, the FDA continues to sleep on duty.

Double the Dose – Rake in the Billions

In 2004 the government-funded National Cholesterol Education Program selected a panel of nine “experts” to review statin drug use and make recommendations as to guidelines doctors should follow to reduce cardiovascular disease.  They recommended that individuals at high cardiovascular disease risk attain LDL levels < 100 mg/dL and individuals at very high cardiovascular risk attain LDL levels < 70 mg/dL (levels that are abnormal, levels which are seldom ever this low in healthy people with no cardiovascular disease). Their advice was published in the marketing journal of the American Heart Association, Circulation.  This “scientific journal” failed to disclose that six of the nine authors had direct financial ties to the makers of statin drugs.
Today, in doctor’s offices around the country, these abnormal cholesterol levels are being pushed on anyone over the age of 40, requiring a double or triple dose of statins or combination with some other toxic drug (like fibrates) to achieve these completely unnatural and unhealthy levels of cholesterol.  In hindsight we can see that these recommendations boosted yearly statin sales by seven billion dollars.  A class-action lawsuit has already been filed against Pfizer for illegal Lipitor promotion.  Many others are sure to follow as this fraud becomes better understood by those who are injured and those footing the bill.
Further highlighting this fraud is a study appearing in the October 3, 2006, issue of the Annals of Internal Medicine.  Researchers reviewed all studies relating to cholesterol-lowering benefits by statin drugs, with a focus on the new abnormally low cholesterol levels promoted by the American Heart Association. Their conclusion, “current clinical evidence does not demonstrate that titrating lipid therapy to achieve proposed low LDL cholesterol levels is beneficial or safe.”  That is a rather shocking conclusion coming more than two years after the fact.  The finding did not faze the statin marketing machine or the prescribing habits of any physician.

Make Vitamin E a Scapegoat

During the time in 2004 that Big Pharma was plotting its statin bonanza it needed to fire cannonballs at its most widely recognized competition, Vitamin E and other antioxidants. No problem. First, in August 2004, the American Heart Association used its marketing magazine to print a bogus article contradicting hundreds of nutritional studies, stating that antioxidants A, C, and E are not effective for cardiovascular disease risk reduction. Then, in November of 2004, with trumpets blaring at their yearly AHA meeting, they make the brazenly fraudulent claim that vitamin E increases the risk of death by 6%!!!
Outside the marketing meeting masquerading as a scientific conference, the chairman, Dr. Raymond Gibbons of the Mayo Clinic in Rochester, Minnesota, was holding a dog and pony show press conference. “I spend all my time trying to tell patients why they should not take vitamin E. Too often in terms of the supplements there’s very scant science. In this area, we have the science. Vitamin E doesn’t work.” He implored his captive audience of reporters to help him convince patients to stop taking Vitamin E and take the “proven” drugs. The next day, all major media ran the story telling consumers vitamin E was dangerous. Program effective. Damage done.
Within weeks the American Heart Association had brainwashed doctors and the American public to actually think vitamin E was dangerous, clearing out the primary competition to statins for the prevention and treatment of cardiovascular disease. Doctors were telling all their patients to stop taking vitamin E. The anti-vitamin rhetoric spread like wild fire through doctor’s offices around the nation and continues to this day.
Within a week the bogus vitamin E information coming from the American Heart Association meeting was debunked. Physician and nutritional expert, Alan Gaby, pointed out all the flaws as well as the safe and effective track record of vitamin E. By April of 2005 the leading antioxidant scientists in the worldhad published a comprehensive review showing the safety of vitamin E up to doses of 1600 IU per day, again debunking the false vitamin E story and explaining the high degree of safety of antioxidant nutrients. The media was nowhere to be found; the public never heard vitamin E was truly safe and vital for immune function, prevention of cognitive decline, and a wonderful nutrient for cardiovascular support.
In July of 2005, the Journal of the American Medical Association published the results of an amazing vitamin E and heart disease study. After tracking 40,000 women for eight years it was proven that vitamin E lowered the risk of cardiovascular death by 24%! However, JAMA authors, going along with the vitamin E smear campaign, concluded that vitamin E was not worth recommending! Any drug with that kind of statistical evidence would be a billion dollar blockbuster. The media failed to look at the study and reported everywhere that vitamin E was not needed, denying women the true information about a wonderful cardiovascular support nutrient.
Likewise, an August 2007 randomized, double-blind, placebo-controlled cardiovascular study published in the Archives of Internal Medicine found that natural vitamin E reduced cardiovascular death or serious cardiovascular disease by a statistically significant 13%, the primary end point of the study.  Natural vitamin E also showed improvement in secondary end points, including a 22% reduction in heart attacks, a 27% reduction in strokes (31% when combined with vitamin C), and a 9% reduction in cardiovascular death.  Once again the study results were hidden deep in the paper, downplayed by the authors, and not correctly reported in the media. And in November the American Journal of Clinical Nutrition reported the results of another randomized, double-blind, placebo-controlled vitamin E study showing that vitamin E was completely safe at doses of 1200 IU per day in patients with existing cardiovascular disease.  Once again the media was nowhere to be found.
It is hard to calculate how many elderly people have been injured and killed by the proclamation not to take vitamin E and to take statins in super-high doses.  Vitamin E is absolutely vital for heart function and healthy immunity in older Americans.  When a statin-taking senior dies the physician never notes the deterioration of health that often begins with taking a statin or increasing the statin dose.  Rather, the physician simply blames the health of the patient for the death – isn’t that convenient.  Thus, statin-induced deaths are hidden and grossly under-reported.

A New Statin Fraud Emerges

The statin golden pot at the end of the rainbow has recently been threatened due to the fact that several best-selling statin drugs have lost patent protection and are now open to generic competition for pennies on the dollar ((Lipitor sales are off 25%).  Newer cholesterol drugs in the pipeline have turned out to be a total bust.  In order to get insurers to keep coughing up unnecessary money Big Pharma had to be creative – and dishonest (no surprise there).
Merck and Schering-Plough have joined forces to market Zetia (which works in the digestive tract differently than a statin) and Vytorin (which is a combination of Zetia and a statin).  By combining a statin in this way generic competition can be avoided.  Either Zetia or Vytorin sell for $3 a day, compared to $0.25 for a generic statin.  By adding Zetia to any other statin or by taking the combination pill cholesterol can be lowered an additional 15%.  This has created a $5 billion dollar share of the statin market for these two drugs.
Is lowering cholesterol an extra 15% worth it?  That is the billion dollar question.  Forbes was the first to blow the lid on what is obviously a rip-off.  The Wall Street Journal is also covering the story.  Vytorin has never been proven to prevent heart attacks, strokes or deaths any better than a plain generic statin.  In 2002 Merck/Schering Plow undertook a study to prove that the combination prevented plaque build up in the arteries better than a statin alone.  The study was completed in April of 2006.  The drug companies are sitting on the results, and now have announced they are changing the primary outcome of the study after it is done – a scientific farce.
It is obvious that the top executives in these companies know the results are not good.  They can’t throw the data away as their marketing campaign was built on the expectation of a favorable outcome of these studies.  Even doctors are complaining about the stalling tactic.  The longer they can stall the longer they can collect their $5 billion in yearly sales, swindling Americans of hard earned money.  This is, unfortunately, an example of typical drug company behavior.  The FDA is of course snoozing on the job – they should be warning consumers of the dangers of lowering cholesterol excessively.

Take Health into Your Own Hands

The medical profession has lost almost all credibility.  There is no short cut to being healthy.  The majority of drugs are best used for a short duration, which is not in the best interest of Big Pharma profits.  Some people in poor health need to be managed with drugs.  Drugs as a tool for general health and prevention are a travesty.  The statin industry is a scam gone wild.  Space in this article has only allowed me to define a few of the primary statin side effects.  There are many more that are seldom explained, including weakened immunity and cognitive decline.  Statins are a slow and insidious poison wherein the side effects gradually get worse the longer a person takes them.  This means that people often don’t realize their decline in health is from the statin, until someone points this issue out to them and they look at how their health in general has deteriorated since being on a statin.  No, it’s not that the person is simply getting older – it’s the statin!  You may read about all the statin side effects for free in my book, Fight for Your Health:  Exposing the FDA’s Betrayal of America (chapters 19-21).
If we want a renaissance in cardiovascular fitness and quality of life in the over 50 crowd then most of the meds need to go in the trash and be replaced with consistent exercise programs, a fresh and organic diet, stress management programs, improved quality of sleep, and appropriate dietary supplements that support fitness and healthy cardiovascular function. Seniors need to have a rightful and respected place in our culture.

Statin Drugs Cause Atherosclerosis and Heart Failure

“Statin Drugs stimulate atherosclerosis and heart failure” is the title of a research study published this past week. It has not made mainstream news at the time of this article writing, but it is of utmost importance to the health of the tens of millions taking statin drugs for cholesterol. The evidence continues to pile up and prove that statin drugs are hazardous to your heart and health.
The study, published in Expert Review of Clinical Pharmacology February 6, 2015, discusses the process of how statin drugs cause the demise of heart health, worsen atherosclerosis and induce heart failure. The study’s authors are located in Japan at the Nagoya City University. If and when this news reaches the American public, the tens of millions of patients on statin drugs with worsening heart disease and heart failure should be flooding their physician’s office and the drug companies’ door with phone calls demanding explanations and reprimand. So far that has not happened.

Vitamin K2

The study presented insightful information describing the physiological mechanisms on how statin drugs cause coronary artery calcification or stiffening of blood vessels perpetuating the atherosclerosis. The plaque build-up occurs because statin drugs inhibit vitamin K2 function in the body. Vitamin K2 protects arteries from calcification. Without proper levels and function of vitamin K2, plaque levels worsen because of negative interaction with the Gla-protein and the inhibition of vitamin K2. This was previously described in a large study in 2012 with the same conclusion – statin use causes increased presence of coronary plaques. They did not identify the link with vitamin K2. The tool that cardiologists use to prevent atherosclerosis actually worsens it.

Mitochondria Damage

The second finding of the study is of little surprise. It shows that statin drugs are toxic to the mitochondria, or the energy producers in cells. Mitochondrial damage in the heart is a downward slope to cardiomyopathy or heart failure. This is a dangerous, although often subtle, effect. Statins impair the heart muscle mitochondria function, severely disrupt ATP production, and alter intracellular signaling proteins. This impairment leads to muscle cell dysfunction and eventually apoptosis or muscle cell death. This is like pouring concrete into the cellular engines of energy production and heart muscle contraction. Statins are notorious for depleting coenzyme Q10 out of the heart muscle and the body. This profoundly interferes with mitochondria function. Statins also interfere with the protein called heme A. Heme A is a component of hemoglobin that helps bind onto oxygen and carry iron to the muscle cells in the heart. Without the ability to transport iron and oxygen to the heart cells, energy production is further compromised. Iron deficits in the heart myoglobin may occur and possibly contribute further to heart failure.

Coenzyme Q10

Statin drugs interfere with coenzyme Q10. This has been documented repeatedly in medical literature with strong evidence. In fact, a black box warning for statin drugs or HMG CoQ reductase inhibitors was proposed to the FDA. The proposed black box warning was:
“HMG CoA reductase inhibitors block the endogenous biosynthesis of an essential co- factor, coenzyme Ql0, required for energy production. A deficiency of coenzyme Q10 is associated with impairment of myocardial function, with liver dysfunction and with myopathies (including cardiomyopathy and congestive heart failure). All patients taking HMG CoA reductase inhibitors should therefore be advised to take 100 to 200 mg per day of supplemental coenzyme Q10.” 
The FDA blocked the attempt of putting a black box warning on statin drugs in 2014. How egregious is that?

Selenium

Another factor discussed in the initial study was the interference of the production of selenium containing proteins. Statin drugs inhibit the biosynthesis of these selenoproteins. One of the most important selenoproteins in the body is a compound called glutathione peroxidase. Its job is to protect the organism, especially muscle tissue, from oxidative damage coming from hydrogen and lipid peroxides. Lack of the glutathione peroxidase enzyme promotes high levels of free radical activity and tissue damage. Blocking the selenoprotein enzyme glutathione peroxidase is akin to pouring gasoline on the fire of inflammation and free radicals, which damages muscle tissue. In fact, the scientists described this blocking of the selenoproteins reminiscent of selenium deficiency induced heart failure, known as Keshan’s disease first identified in the 1930s. Scientists have strongly recommended that individuals suffering from non-ischemic heart failure have their selenium levels tested. This is a blood test that is readily available. Get an RBC selenium level checked at your next appointment. Certainly our selenium depleted foods and soils are not helping this situation when combined with drug-nutrient induced deficits.

Other Side Effects

Expand this picture further. We have skeletal muscle, cardiac muscle, and smooth muscle. The side effects of statin drugs are often discussed as skeletal muscle weakness and pain and in recent years the increased development of heart failure (cardiac muscle failure). This is most often in the context of high dose statins. There are, however, other side effects that may be linked with statin drugs and how they affect mitochondria. Common side effects with the drug simvastatin include headaches and constipation. One doesn’t normally think of headaches and constipation concerns linked with mitochondria, but they can be. Both the nervous system and smooth muscles have high levels of mitochondria. Bowel motility is dependent upon smooth muscle function and nervous system activity. When there is a disruption in the health of mitochondria in the body, one of the symptoms may be constipation.
This is the same with migraines. Some types of headaches, i.e. some subtypes of migraines are related with mitochondria dysfunction. Joint pain and tendon problems may also be related. Don’t forget the brain and side effects of being forgetful or depressed. Our brain desperately needs healthy mitochondria to function effectively. It is common to dismiss these symptoms, attributing them to poor diet, stress, or aging. Yet, how many statin users have the common symptoms of constipation, headaches, joint pain, and feel a little less energetic, forgetful, and weaker than they did a few years ago and chalk it up to aging. Often they go to their physician and because they do not have outright symptoms of rhabdomyolysis and liver failure from the statin drug, it is chalked up to stress and getting older. The traditional medical and research communities are heavily debating these side effects and are not owning up to the real damage caused by statins. Many are looking for more ways to prescribe statins other than for cholesterol problems.
The question remains:  how many people are going to suffer further heart disease with sky-rocketing rates of heart failure and subsequent loss of function and life linked with statin induced side effects? How many burgeoning statin drug class action law suits will it take to stop the pharmaceutical industry from this massive debacle and cover-up resulting in human tragedy? One is too many. It is time for the medical and pharmaceutical industry to acknowledge the truth and look at real solutions for heart disease.

Proactive Steps

If you are on statin drugs for any reason, make sure that you are taking at least 200 mg of coenzyme Q10 per day. Higher amounts, up to 600 - 800 mg, may be used for serious fatigue, mitochondrial injury, and cardiomyopathy disorders. The form of coenzyme Q10 plays a substantial role in how well coenzyme Q10 is absorbed, gets into the blood stream, and where it is used in the cell. Wellness Resources recommends the use of water and fat soluble coenzyme Q10 in either ubiquinone or ubiquinol forms.
Supporting selenium levels is also of primary concern. Brazil nuts, some seafood, mushrooms, asparagus, poultry and beef may provide good dietary sources of selenium or consider nutritional supplementation for standardized activated forms of selenium, like seleno-methionine.
Vitamin K2 must be present in adequate amounts to offset the drug-nutrient interaction. It is found in fermented foods and limited quantities in animal products. It is also produced by healthy gut bacteria and available in supplemental form.
Protecting the mitochondria from further oxidative damage should also be a priority. This is irrespective of statin drug use. Antioxidant rich, deep colored fruits and vegetables help protect the mitochondria from oxidative stress. Nutrients described above and others such as resveratrol, carnitine, bacopa monnieracurcumin, all B vitamins, vitamin C, vitamin E, K1, NAC, and lipoic acid are just some of the nutrients essential for protecting the heart from ischemic/heart attack damage, heart failure, and mitochondria injury.
Interestingly, in the last ten years melatonin has been found to protect the heart after heart attack injury in animal studies. Melatonin stopped heart cells from dying and protected the structural integrity of the mitochondria in heart cells and avoided marked worsening of heart damage. This too can be added to the arsenal of support for protecting the heart.
The link of melatonin and its ability to protect the heart and mitochondria leads into another tangent – the thought of sleep deprivation, sleep hygiene, and light exposure in the body and its effect on the body. With heart disease, heart failure and mitochondrial disorders at epidemic levels, it makes one question the age of electricity, sleep deprivation, and compromised melatonin production as causing a fundamental shift in the health of our heart and mitochondria. If scientists ever tackle this issue, it will be an astronomical feat for any conclusion to occur but it is an interesting thought. Until then, find ways to improve your melatonin status and improve sleep to see how you and your heart feel.
The researchers from the headline study said “Thus, the epidemic of heart failure and atherosclerosis that plagues the modern world may paradoxically be aggravated by the pervasive use of statin drugs. We propose that current statin treatment guidelines be critically reevaluated.” They were polite in their request and recommendations, but what about you? Are you going to follow the mainstream herd mentality, or are you going to look at the physiology and stand up for your health? Talk to your cardiologists and see if they understand these principles of physiology. If they did, they should be the first to stop prescribing these dangerous meds. Take charge of your health today!

Statins & Type 2 Diabetes: The Straw that Breaks the Camel’s Back

Two recent studies have shown that high-dose statin therapy can induce the onset of type 2 diabetes, worsening the health of those who are already in poor health.  These studies lend further credence to the FDA’s recent warning for patients across the country to get off high-dose statin therapy due to concerns of muscle damage. Let’s not forget that the heart is a muscle.
The new study takes into account all statins that are commonly used, and was published today in the Journal of the American Medical Association1.  It found that high-dose statin therapy increased the risk of type 2 diabetes by 12% compared to low-dose statin therapy. Of course, these studies never compare the risk of a drug to someone actually becoming more fit and healthy through natural means, as the increased risk would be so dramatic the drug would have to be pulled from the market. In this case the researchers are comparing a high dose of poison to a lower dose of poison. The new study is extremely embarrassing to the statin industry, as it was picked up by news outlets around the world and ran as a headline. 
Performing statistical mumbo-jumbo the researchers concluded that the benefits still outweigh the risks, as they implied that more cardiovascular deaths were prevented than diabetes caused. It is always fascinating to watch a Big Pharma calculator in action – no matter what data is put in a positive spin on taking the drug is always the answer. 
A second study published in April in the Journal of the American College of Cardiology2 found similar results, while focusing only on the statin Lipitor. However, this study analyzed more details of the health status of those before they went on high-dose statin therapy.  It found that those in the worst metabolic condition (higher fasting glucose, more overweight, higher blood pressure, and higher triglycerides) were the most likely to develop new onset type 2 diabetes. This means that high-dose statin therapy was more likely to push a person into type 2 diabetes if they were already knocking at the door.  And in direct conflict with the risk/benefit conclusion of the above study, this study found that those with new onset type 2 diabetes had a higher risk for major cardiovascular events.
These studies highlight the extreme difficulty physicians have in titrating poisons to be “appropriate” for any person, especially as their health worsens.  Unfortunately, the majority of statin-prescribing physicians don’t think about actual risks of what they are doing.  To the contrary, the worse off the metabolic health of the patient, the greater the number of toxic substances are prescribed, typically in the highest amount possible.
The most valuable asset you have is your health. Protect it and preserve it. If you get off track make a diligent effort to fix your issues. The failure to do so on your part will land you in front of a pill-pushing Big Pharma advocate, a supposed health professional who will now titrate poisons on your behalf, a person who typically has no clue how those poisons will actually behave in your body. It is a shame that the subject of medicine has been reduced to such a barbaric approach to managing the health of millions. It is little wonder that our health care costs skyrocket while the life expectancy of Americans dramatically lags behind other developed nations and is actually headed in the wrong direction.

Statins CAN cause heart disease - Shock research warns drug risks hardened arteries

CONTROVERSIAL drug statins can actually increase the risk of heart disease, shock new research has shown.
People taking the drugs are more likely to suffer from hardening of the arteries, a leading cause of heart problems.

In addition, researchers found the drugs block a process that protects the heart.

This can “cause, or worsen, heart failure”, according to a study.

The lead author says: “I cannot find any evidence to support people taking statins.”
The findings, published in Expert Review of Clinical Pharmacology, will add to the debate surrounding the drugs, which are routinely given to up to 12 million patients in the UK, or around one in four adults.

Supporters say they save lives by lowering cholesterol and UK health regulators say they are safe.

Oxford professor Sir Rory Collins has warned that overstating concerns about statins could “cause very large numbers of unnecessary deaths from heart attacks and stroke”.

Opponents have pointed to the side effects, such as skeletal weakness and muscle pain, and say the risks outweigh the benefits.
Now Professor Harumi Okuyama, whose team studied a series of more than 20 major research papers on the drugs, says they could cause heart disease.

Dr Okuyama, of Nagoya City University, Japan, said: “We have collected a wealth of information on cholesterol and statins from many published papers and find overwhelming evidence that these drugs accelerate hardening of the arteries and can cause, or worsen, heart failure. I cannot find any evidence to support people taking statins and patients who are on them should stop.”

The researchers say the hypothesis that statins protect the heart by lowering cholesterol is flawed and that high cholesterol is not necessarily linked to heart disease.

They also found statins have a negative effect on vital body processes linked to heart health.

They discovered patients taking the drugs were more likely to have calcium deposits in their arteries, a phenomenon directly linked to heart attacks.

This is because statins block a molecule needed for the body to produce a vital K vitamin, which prevents calcification of the arteries.

Dr Okuyama and his team say many earlier industry-sponsored studies, which show the benefits of statins, are unreliable.
They claim this is because they were carried out before new European regulations were introduced in 2004 which insisted on all trial findings, both negative and positive, being declared.

The study states that before these new rules came into effect “unfair and unethical problems were associated with clinical trials reported by industry-supported scientists”.

Dr Okuyama’s team looked at studies before and after 2004.

They found: “The epidemic of heart failure and atherosclerosis (hardening of the arteries) that plagues the modern world may paradoxically be aggravated by the pervasive use of statin drugs. We propose that current statin treatment guidelines be critically re-evaluated.”
Dr Malcolm Kendrick, who has studied heart health and statins, said: “This study demolishes the argument that these drugs should be prescribed to anyone, as the harms clearly outweigh any previously suggested benefits.”

Dr Peter Langsjoen, a heart specialist based in Texas who is co-author of the study, said: “Statins are being used so aggressively and in such large numbers of people that the adverse effects are now becoming obvious. These drugs should never have been approved for use. The long-term effects are devastating.”

A spokesman for the MHRA, the Government drug regulator, said: “The benefits of statins are well established and are considered to outweigh the risk of side effects in the majority of patients. "Any new significant information on the efficacy of statins will be carefully reviewed and action be taken if required"

Statins Linked to Raised Risk of Type 2 Diabetes



Large Finnish study found a nearly 50 percent increase in people taking cholesterol-lowering drugs
WEDNESDAY, March 4, 2015 (HealthDay News) -- Cholesterol-lowering statin drugs may significantly increase a person's risk of developing type 2 diabetes, a new study from Finland suggests.
Researchers found that statins were associated with an almost 50 percent higher risk of developing type 2 diabetes, even after adjusting for other factors.
Statins appear to increase the risk of type 2 diabetes in several ways, the researchers said. One is that the drugs can increase a person's insulin resistance, and the other is that the cholesterol-lowering drugs seem to impair the ability of the pancreas to secrete insulin, according to the report.
Commenting on the study, Dr. Ronald Goldberg, director of the Lipid Disorder Clinic and associate director of the Diabetes Research Institute at the University of Miami, said the researchers "show evidence that statins increased insulin resistance, and that the people who developed diabetes appeared to have less ability to respond to the insulin resistance by making more insulin."
The study authors noted, however, that their research only found an association between statin use and diabetes risk. And since the study was limited to white men, it's not clear if the findings would apply to women or other racial groups.
More than 29 million people in the United States have diabetes, according to the American Diabetes Association (ADA). Type 2 diabetes occurs when the body becomes resistant to insulin, a hormone needed to process the sugars found in foods. To compensate, the body produces more insulin. Excess weight and a sedentary lifestyle are two important risk factors for type 2 diabetes, according to the ADA.
Prior studies have indicated that statins may increase a person's risk of diabetes, the authors said in background information in the study. However, these earlier studies were focused mainly on statins' role in preventing heart disease, not on their potential diabetes risk.
In this new study, University of Eastern Finland researchers tracked the effects of statin treatment in almost 9,000 men without diabetes over the course of six years. The men were between 45 and 73 years old. One in four of the men was taking a statin at the beginning of the study.

The health of the men was followed for nearly six years. During that time, 625 men were newly diagnosed with type 2 diabetes, the researchers said. Even after other risk factors were accounted for, people treated with statins were 46 percent more likely to develop diabetes than those not treated with statins.
The diabetes risk increased with the dosage taken of the statin drugs simvastatin (Zocor) and atorvastatin (Lipitor), the researchers said.
Digging a little deeper, the investigators found that statins decreased insulin sensitivity by 24 percent, and insulin secretion by 12 percent. The more simvastatin and atorvastatin that people took, the more their ability to use and produce insulin suffered.
High-dose simvastatin was associated with a 44 percent increased risk of developing diabetes, while for low-dose simvastatin the increased risk was 28 percent. High-dose atorvastatin was linked to a 37 percent increased diabetes risk, the study found.
Based on these findings, physicians will have to weigh risks versus benefits before prescribing statins, said Dr. Al Powers, director of the division of diabetes, endocrinology and metabolism at Vanderbilt University Medical Center.
Patients with pre-diabetes will need particular consideration, given that they are already on the verge of developing type 2 diabetes, Powers said.
"That's a situation where the physician and the patient must weigh the risks and benefits and decide what to do," Powers said.
On the other hand, statins can be prescribed without concern to people already diagnosed with type 2 diabetes, since they are already being treated for the condition, he added. "Those patients should continue their statin treatment," Powers said.
Goldberg expects that most heart patients who need statins will continue to receive them, but with close monitoring of their blood sugar levels.
"If your risk for heart disease is high, the benefit of statin therapy is so important that most physicians and most patients, when it's explained to them, will be willing to incur the increased risk of diabetes in favor of the added benefit to preventing heart attack and stroke," Goldberg said.
Dr. Alan Garber, a professor at Baylor College of Medicine, said that statin users with blood sugar levels beginning to creep up can likely head off type 2 diabetes through diet and exercise. Garber is the editor of the journal Diabetes, Obesity and Metabolism.
"The solution is lifestyle modification with diet and exercise. You should do that for high cholesterol, anyway," Garber said. "There's no simple cure-all for all the risk factors in life. It's clear that a single pill isn't going to supplant individual self-management. Patients have to learn to take care of themselves."
The findings were published March 4 in Diabetologia, the journal of the European Association for the Study of Diabetes.

2016年12月22日星期四

Four Brazil Nuts Once a Month

One of the craziest studies I read all year involved feeding people a single serving of Brazil nuts to see what it would do to the cholesterol levels of healthy volunteers. They gave ten men and women a single meal containing zero, one, four, or eight Brazil nuts, and found that the ingestion of just that single serving almost immediately improved cholesterol levels. LDL, so-called “bad” cholesterol levels in the blood, was significantly lower starting just nine hours after the ingestion of nuts, and by no insignificant amount, nearly 20 points within a day. Even drugs don’t work that fast. It takes statins around four days to have a significant effect.

But that’s not even the crazy part.

The researchers went back and measured their cholesterol five days later, and then 30 days later. Now, keep in mind they weren’t eating Brazil nuts this whole time. They just had that single serving of Brazil nuts a month before and their cholesterol was still down 30 days later. It went down and stayed down, after eating just four nuts… That’s nuts!

And no, the study was not funded by the Brazil nut industry.
Interestingly, four nuts actually seemed to work faster than the eight nuts to lower bad cholesterol and boost good cholesterol. These results suggest that eating just four nuts might be enough to improve the levels of LDL and HDL for up to 30 days, and maybe longer—they didn’t test past 30.

Now normally, when a study comes out in the medical literature showing some too-good-to-be-true result like this, you want to wait to see the results replicated before you change your clinical practice, before you recommend something to your patients, particularly when the study is done on only ten people, and especially when the findings are literally just too incredible to be believed. But when the intervention is cheap, easy, harmless, and healthy—eating four Brazil nuts a month—then, in my opinion, the burden of proof is kind of reversed. I think the reasonable default position is to do it until proven otherwise.

They concluded a single serving was sufficient “without producing liver and kidney toxicity.” What they’re referring to is the high selenium content of Brazil nuts—so high that four eaten every day may actually bump us up against the tolerable daily limit for selenium, but not something we have to worry about if we’re just eating four once a month.

I’d be curious to hear if anyone experiences similar results. Even if the study was just a fluke, Nuts May Help Prevent Death by improving the function of our arteries (Walnuts and Artery Function) and fighting cancer (Which Nut Fights Cancer?) and inflammation (Fighting Inflammation in a Nut Shell).

Even eating nuts every day does not appear to result in expected weight gain (Nuts and Obesity: The Weight of Evidence), so enjoy!

2016年11月4日星期五

The facts about flaxseed and hypertension

A Winnipeg scientist and his team have shown that the humble flax seed has the power to dramatically reduce high blood pressure - a development that could help cut the incidence of cardiovascular disease by as much as 50 per cent.

BY JOEL SCHLESINGER
Winnipeg Health Region
Wave, January / February 2013

Dr. Grant Pierce is not a fish person.

"I just don't like the taste," he says simply.

The Winnipeg scientist's dislike of fish may seem like a trivial detail, especially when raised in the context of his research into the health benefits of certain types of foods.

But it is, nonetheless, one of the reasons why Pierce decided to embark on a major research project more than 10 years ago that now promises to change much about how we treat high blood pressure and cardiovascular disease in Canada and around the world.

At the time, Pierce, Executive Director of Research at St. Boniface Hospital, was helping to launch the newly minted Canadian Centre for Agri-Food Research in Health and Medicine (CCARM). The research facility, a partnership between St. Boniface Hospital, the University of Manitoba and Agriculture and Agri-Food Canada, is dedicated to exploring the health benefits of foods, particularly those grown on the Prairies.

As Pierce, a physiology professor in the Faculty of Medicine at the University of Manitoba, reviewed his options, he started to focus on flax seed, and with good reason.

New research at the time suggested that significant health benefits could be derived from omega 3 fatty acids found in fish. Studies indicated that, among other things, omega 3 fats could boost brain development and promote heart health.

Flax also contains omega 3 fatty acid, but it differs from the kind found in fish. Omega 3 fatty acids eicosapentaenoic (EPA) and docosahexaenoic acid (DHA) are found in fish, while a third omega 3 called alpha-linolenic acid (ALA) is found in flax.

At the time, it was thought that the omega 3 fatty acids found in fish were more beneficial than the kind found in flax. As a result, the health spotlight shone on omega 3-laden fish, while the humble flax seed remained in the shadows - a healthy food to be sure, but not necessarily as beneficial as some others.

Pierce decided to test that theory.

"When it came to looking at flax seed, I was persuaded by the effect of fish and the omega 3 fatty acids they contain and their effect on cardiovascular health," says Pierce.

"You hear all the time that the omega 3s found in fish are very good for brain development and a variety of things," he says. "Well, if you follow this thinking logically, that means vegetarians haven't had good brain development as they grew up. I don't go for that. They must have had their omega 3 fatty acids from another source, and I bet you they fared just as well."

Pierce figured he probably wasn't the only one who didn't care for fish, and concluded that there might be some interest in researching alternative food sources to fish-based omega 3s. And since flax is grown in abundance in Manitoba, the plant seemed like the perfect choice for the first long-term study at CCARM.

"If the fatty acid in flax is structurally different than fish, then potentially it's biologically different," says Pierce. "In other words, it may have a different biological effect. It may be worse. It may be better. And we wanted to examine that."

Now, more than 10 years later, following a series of studies and clinical tests involving 110 people, Pierce believes flax is ready to step out from the shadows and claim its rightful place as one of nature's true super foods. That's because he and his team have recently completed a clinical trial demonstrating that flax, depending on how it is consumed, has the potential to significantly reduce blood pressure, thereby possibly decreasing the incidence of stroke by as much as 50 per cent and heart attack by about 30 per cent. The findings mean, in effect, that the tiny brown seeds derived from the pale blue flowering plant grown across Manitoba could be as powerful as any blood pressure medication on the market today.

The health implications flowing from the research are huge. Hypertension (high blood pressure) is a leading cause of cardiovascular illness, including stroke and heart disease. In Canada, cardiovascular disease is one of the leading causes of death, accounting for an estimated 29 per cent of all deaths, or about 70,000 people each year, according to the Heart and Stroke Foundation of Canada. In Manitoba, a report produced by Manitoba Health says about 235,683 people in this province had hypertension in 2010/11. That represents about 27.2 per cent of the population 20 years of age or older, compared to 21.7 per cent in 2000/01. The report also says about 1,514 people in Manitoba suffered a stroke in 2009/10, while 2,420 had a heart attack.

In addition to shedding light on possible new approaches to treating and preventing disease, the research also underscores the importance of the work being done at CCARM, located at the St. Boniface Hospital Research Centre.

Pierce helped launch CCARM in 1999 with a view to filling a gap in the medical research world. As he explains, drug companies spend billions of dollars annually on the research and development of new drugs, but comparatively little is spent on researching the health benefits of particular foods or how they might be used. The reason is that drug companies can't patent the information that might come from researching the health benefits of a particular food, consequently there is no incentive to spend money researching its value. Even the health food and supplement industry - a multi-billion dollar business - spends relatively little to actually research the claims often made for their products.

That's where CCARM comes into play. Researchers at the centre are dedicated to researching nutraceuticals or functional foods that may have some health-related benefits. A functional food is something like muffins that contain a dose of bran. A nutraceutical is an extract like ginseng or Echinacea extract.

Pierce says the goal is simple: "Either we prove that these foods or nutrients are of benefit to our health, or we prove that they aren't. If the marketing claims hailing their benefits turn out to be unsupported by good scientific data, people can stop wasting their money on products that they thought were good for them."

From the outset, the vision at the centre has been ambitious, focusing on long-term, complex studies that can be costly. As a result, it is important to look for locally-grown foods that are potentially healthy and marketable - two factors that can help attract potential investors.

The research into flax is a good example of how that relationship works. The study's primary goal was to determine whether flax had significant health benefits, and involved dozens of willing participants and a host of medical researchers and clinicians at the University of Manitoba and St. Boniface Hospital. But it also drew on the expertise and support of the Canadian International Grain Institute, the Food Development Centre in Portage la Prairie, Canada Bread and the federal and provincial governments, who were interested in the economic implications of discovering the health benefits of a locally-grown crop.

From the outset, Pierce knew that his research would likely confirm that flax did indeed have a number of health benefits. One area he wanted to investigate was whether it would help reduce cholesterol.

High cholesterol contributes to the buildup of plaque in the arteries, which restricts the flow of blood and can cause heart attacks.

"Omega 3 fatty acids are anti-inflammatory and we now know that inflammation is an important component of heart disease, creating blockages in your arteries and altering how your arteries work," he says.

The first step in the multi-year research project involved basic lab work - looking at cells in a petri dish under a microscope. Once the basic tests were completed, the team began animal testing. Lab animals were fed a high-cholesterol diet. While the control group animals received regular food, others had milled flax seed added to their diet. The animal studies yielded impressive results, showing flax had the potential to significantly reduce the cholesterol-filled blockages in arteries. Further animal studies also demonstrated that flax prevents cholesterol buildup from a diet high in trans-fats.

The research team found other benefits. When researchers induced conditions in flax-fed animals that resembled heart disease, their hearts were found to have added resistance to developing an irregular heartbeat.

"One of the major complications in a heart attack is that the heart will go into something called an arrhythmia, or an irregular heartbeat, and ultimately, if it's severe enough, that's what kills many patients," says Pierce. "Flax prevented some of the most dangerous arrhythmias."

In addition, researchers also discovered that flax made the animals' smooth muscle lining in their arteries relax more than the control group. This relaxing effect on arteries could potentially reduce the incidence of adverse cardiovascular events - such as heart attacks or strokes, which occur when blood flow is substantially reduced to parts of the brain. The findings were significant enough to prompt more research involving clinical trials in humans with heart disease.

"Because of those three effects we found in the animals, we got pretty excited," Pierce says. "The animal work was so positive, we knew it was time to move on to human studies to see if it's beneficial to us."

Those studies started four years ago. Even though the first phase of the clinical study involved only a year of monitoring patients, Pierce says a lot of groundwork had to be done first. His team needed to carefully design an experiment that would show as conclusively as possible that flax does or does not benefit human health.

Pierce hypothesized that previous studies that had shown minimal cardiovascular health benefits from flax had more to do with the design of the studies than with the plant itself. So he and his team carefully built their study from the ground up, with financial support from the Canola Council of Canada, Flax 2015, the Flax Council of Canada, the Agri-Food Research Development Initiative, St. Boniface Hospital Foundation and a variety of other companies and organizations.

Before working with patients suffering from heart disease - a group that could dramatically show the most potential benefit - the team ran a number of mini-trials on healthy individuals to answer a number of questions, which arose earlier in the research.

"That's why the animal work is done, and prior to going into the clinical trials, you work on healthy people first. There were some basic questions that needed to be answered prior to setting up a major trial in a diseased population," says Pierce.

One of the most important of these questions was how much flax would a patient need to ingest in order to achieve optimal results? But before they could find an answer to this problem, they had to figure out the best way for the patients to ingest flax. Was it better to eat flax as whole seed, as a milled product or as an oil?

During this part of the research, they discovered that patients eating whole seeds showed no increase in omega 3 fatty acids in their blood. But significant levels of omega 3 did show up in the blood tests of participants ingesting flax oil or the milled product.

With that problem solved, Pierce and his team moved onto a trial to determine how much flax seed someone would have to consume in order to derive a benefit.

Eventually, they determined that 30 grams of milled flax provided a dose of ALA that would likely provide heart-healthy benefits. But uncertainty persisted because flax seed omega 3 oils (ALA) have a different molecular structure than the (DHA and EPA) omega 3s found in fish.

In a nutshell, the ALA found in flax has a shorter molecular structure. This type of beneficial fat is also found in walnuts, hemp seed, kiwis, canola and soybean, but flax contains the highest concentrations.

"The only difference amongst different omega-3 fatty acids we found was the way they're absorbed," explains Pierce. "If I gave you a pill that contains fish oil and a pill that contains flax oil, the EPA and DHA seemed to be absorbed a little bit better, so you have to take a little bit more of the flax oil to get the ALA levels in your bloodstream to a level equivalent to the fish oils."

Yet, arguably, the most important research work, contingent to the success of the larger clinical research puzzle, was developing food products that would contain enough flax to be beneficial while still being palatable.

And that is not an easy thing to do, according to Dr. Michel Aliani, Director of the Weston Sensory and Food Research Centre in the Department of Human Nutritional Sciences at the University of Manitoba, and a member of the CCARM research team.

Flax on its own is not exactly tasty. The seed is bitter and quite granular, potentially making any product containing it bland, dry and largely unappealing. "We knew more or less that the food would be healthy, but the challenge is whether people can eat it on a daily basis," says Aliani.

That's where Canada Bread and the Food Development Centre in Portage la Prairie stepped in. They developed food products using flax donated by Pizzey's Milling and Glanbia Nutritionals. From buns, bagels, biscuits and muffins to pasta and snack bars, they developed a variety of baked goods and other products that would appeal to clinical trial participants' tastes.

"Developing foods that contain the required amount of flax has been a major challenge in and of itself, let alone making them tasty," he says. "We had to have 30 grams of flax seed in one muffin or bagel, and that's huge (equal to three heaping tablespoons of flax) because it amounts to about one-fifth to one-sixth of the entire muffin or bagel," he says. "The study participants had to eat one of these per day and this was a very long study."

Researchers had to figure out how to include that much flax into a recipe without compromising the integrity of the food product. Would a muffin or bagel with that much flax even hold together?

"Even today," Aliani says, "recipes for future studies are constantly being honed, yet what they have discovered so far is that certain ingredients make flax more palatable. Raisins and cinnamon, for instance, combine to mask flax's bitterness."

With years of painstaking background work complete, it was time to move on to the heart of the research - clinical trials with patients who had cardiovascular disease. "We knew from the animal work that flax seems to reduce atherosclerosis, arrhythmia and help relax arteries," Pierce says. "So we wanted a population of patients with those types of problems."

They found a good match in the patients under the care of Dr. Randy Guzman, Director of the I.H. Asper Clinical Research Institute and Vascular Research at St. Boniface Hospital and an associate professor of surgery in the Faculty of Medicine at the University of Manitoba. His patients suffered from peripheral arterial disease, a condition that clogs arteries and blocks blood flow. "These are patients with arterial problems outside of the chest - or cardiac area - and instead, they often have problems in their lower extremities," says Guzman. "The same plaques that block up the arteries that feed blood to the heart can block up other arteries, like in the legs."

About 80 per cent of the patients were on medication for high cholesterol while 75 per cent took medication for high blood pressure. Because these patients are considered to be very ill, even though they're under medical care and making efforts to improve their health, Pierce says they were ideal candidates for the clinical phase of the study. "They have a high incidence of heart attacks and strokes. They have a lot of arrhythmias, and they have all the characteristics that made us think, 'Hey, this is exactly the group that flax seed may help'."

Although the study set out to measure cholesterol levels, with the hypothesis that flax would reduce blood cholesterol over the course of a year, Pierce says they discovered an unexpected and pleasant surprise. Patients' blood pressure fell.

"Approximately 75 per cent of the patients who came into our trial were hypertensive," Pierce says, adding their average blood pressure was 158 millimetres mercury (mmHg) systolic over a diastolic of about 81 mmHg. "These patients were already on anti-hypertensive drugs and still their blood pressure was poorly controlled, partly because they had so many things going on with them that the physician can't keep up in treating all of the problems."

After a month into the trial, their blood pressure decreased and continued to fall until the six-month mark when it stabilized. By the end of the study, the average study participant's blood pressure decreased 15 millimetres mercury (mmHg) systolic and seven mmHg diastolic.

At first, Pierce wasn't sure what to make of the results. "I'm not a blood pressure researcher, so, to be honest, when we got the results, I said, 'Hmm, okay, I guess these are good. Let's consult with some hypertension experts,'" he says. "Their response was, 'Your results are fantastic.' So we went into the blood pressure literature and that's when we realized, 'Wow! We have a major effect here'."

Guzman concurs with the results. "It's a significant finding and the magnitude is substantial," he says. "The exact mechanisms as to how high blood pressure can cause heart attacks or strokes is complicated," says Guzman. "But the bottom line is if you can reduce blood pressure in patients, you can also decrease their risk of having a stroke or heart attack."

Pierce attributes the reduction in blood pressure to three main ingredients in flax:

Omega 3 fatty acids: These are known to reduce inflammation, and a buildup of plaques in the artery walls is suspected to be a by-product of an immune system response to high-fat diets, stress and other factors that lead to arterial inflammation.
Fibre: Flax is high in soluble fibre, which absorbs bad fats from the body, reducing cholesterol levels and blood pressure.
Lignans: These are potent antioxidants, more potent than Vitamin E.
Pierce believes it was these three ingredients working together that created the synergistic effect that reduced the study participants' blood pressure during the trial.
"You have to remember, one millimetre difference is a huge impact on heart attacks and stroke," he says. That's a result even better than those found from consuming fish. "Fish can reduce blood pressure in hypertensive patients by about four millimetres mercury systolic, so it's nowhere near the level for flax." Furthermore, flax may be more beneficial than fish because it contains less cholesterol than fish.

In addition to a drop in blood pressure, the participants also experienced a cholesterol reduction of about 10 per cent, but Pierce says those findings are currently being written up for publication in a medical journal later this year.

But Pierce says it's the blood pressure findings that are the most compelling at this stage. No other food or supplement comes close. "There's no comparison. Flax seed is better than any other dietary intervention ever shown," he says. That includes the DASH diet (Dietary Approaches to Stop Hypertension), the Mediterranean-style diet prescribed to patients with high blood pressure. "And it's at least as good as many of the drugs that are on the market today," he says.

For Pierce, the findings are exciting.

"I would hazard to say this is the most significant finding our lab has produced, and I doubt that I will ever find anything better," he says. "If this has an influence on reducing heart attacks and stroke by as much as the research suggests, I don't think it gets much better than that."

Still, the research is only getting started. "Our paper on flax and hypertension is currently being revised for publication in the best heart journal in the world," he says "and we continue to learn more about how it works from animal trials."

Aliani says like any good science, Pierce's research has opened up many new avenues of investigation. "In scientific research, if you have a question, and answer it - case closed - that's not really good science," says Aliani, who is now working on a study investigating flax's benefits for Type 2 diabetes patients. "In good science, the answer to one question should open a lot of others, and that's the case here."

Indeed, questions abound for Pierce. A lot of research is still left to do.

"For example, these patients were on hypertensive medication so, really, I don't know whether flax reduces blood pressure in these patients on its own, or did it boost the effects of the drugs?" he says. "In our next trial, that's what we want to look at - take patients who are not on drugs yet and see if we can reduce the number of them who end up taking drugs, or eliminate the need for them to go on anti-hypertension drugs altogether."

"The good part is that past work shows flax does not reduce blood pressure in people who are not hypertensive. Our study confirms that." In other words, people with normal blood pressure won't lower their blood pressure where they may be at risk of passing out.

Eventually, Pierce would like to examine whether flax can help prevent high blood pressure. "Technically, as a scientist, I cannot say it (flax) will prevent the development of high blood pressure because you'd need another study to determine if that's the case," he says. "That's a super study, one we'd love to do - it won't be the next study we do - but honestly, that's where I believe the real gold is; that's where I believe the real beneficial effects are to be found. If it does prevent or delay disease, then it is a realistic approach for reducing health-care costs in Manitoba and Canada."

2016年11月3日星期四

Flax Seeds Can Have Profound Effect on Hypertension

A recent article in the journal, Meat Scienceacknowledged that a sector of the population perceives meat as a food that is detrimental to their health because of studies associating meat consumption with heart disease and cancer. So, the article continues, meat consumers may look for healthier food alternatives as a means to maintain good health, which represents a good opportunity for the meat industry to develop some new products. The industry felt that natural foods could be added to meat to reach those health-oriented consumers by boosting antioxidants levels, for example. Foods like flax seeds and tomatoes are healthy, associated with reduced risks of cancer and cardiovascular disease. So by making flax-y tomato burgers, they figure they can reduce saturated fat intake and maybe eat less sugar somehow. Wouldn’t it be easier to just cut out the middle-cow and eat flax seeds ourselves?
Flax seeds have been described as a “miraculous defense against some critical maladies.” I’m a fan of flax, but this title seemed a bit over-exuberant; I figured something just got lost in translation, but then I found a prospective, double-blinded, placebo-controlled, randomized trial—you know how hard that is in a nutrition study? For drugs, it’s easy: you have two identical looking pills, one’s active, one’s placebo, and until the end of the study, neither the researcher nor the patient has any idea which is which, hence “double blind.” But people tend to notice what they’re eating. So how did they sneak a quarter cup of ground flax seeds into half of the people’s diets without them knowing? They created all these various flax or placebo containing foods, and even added bran and molasses to match the color and texture, so it was all a big secret until six months later when they broke the code to see who ate which.
Why test it on hypertension? Because having a systolic blood pressure over 115—that’s the top number—may be the single most important determinant for death in the world today. If you take a bunch of older folks, most of them on an array of blood pressure pills, and don’t improve their diet at all, despite the drugs, they may start out on average hypertensive and stay hypertensive six months later. But those who were unknowingly eating ground flaxseeds every day, dropped their systolic blood pressure about ten points, and their diastolic, the lower number, by about seven points. That might not sound like a lot, but a drop like that could cut stroke risk 46 percent and heart disease 29 percent, and that ten point drop in the top number could have a similar effect on strokes and heart attacks. And for those that started out over 140, they got a 15-point drop.
In summary, flaxseed induced one of the most potent antihypertensive effects ever achieved by a dietary intervention. In other words, the magnitude of this decrease in blood pressure demonstrated by dietary flaxseed, is as good or better than other nutritional interventions and comparable to many drugs, which can have serious side effects. And they’re not exaggerating about the comparable to drugs bit. The flax dropped systolic and diastolic up to 15 and 7. Compare that to powerful ACE inhibitors like Vasotec, which may only drop pressures five and two, and calcium channel blockers like Norvasc or Cardizem which drop pressures eight and three. Side effects of these drugs include a large list of serious medical issues, as seen in my video Flax Seeds for Hypertension, compared to the side effect of flax seeds, “its pleasant nutty flavor.”
During the six-month trial there were strokes and heart attacks in both groups, though. Even if the flax seeds can cut risk in half, any avoidable risk is unacceptable. Isn’t high blood pressure just inevitable as we get older? No – the prevalence of hypertension does increase dramatically with age, but not for everyone. People who eat more plant-based diets or keep their salt intake low enough tend not to exhibit any change in blood pressure with advancing age. It’s always better to prevent the disease in the first place.